Semaglutide vs Insulin Glargine: side-by-side comparison
Semaglutide (GLP-1 receptor agonist) and Insulin Glargine (Long-acting insulin analogue) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Semaglutide | Insulin Glargine |
|---|---|---|
| Therapeutic class | GLP-1 receptor agonist | Long-acting insulin analogue |
| CAS | 910463-68-2 | 160337-95-1 |
| ATC | A10BJ06 | A10AE04 |
| Molecular weight | 4113.6 g/mol | 6063 Da |
| Brands with this active ingredient | 2 | 1 |
What they share
Semaglutide and Insulin Glargine share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Semaglutide acts by a different mechanism than Insulin Glargine, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Semaglutide: Semaglutide binds and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta and alpha cells, the central nervous system and the gastrointestinal tract. Insulin Glargine: Insulin glargine binds the insulin receptor with similar affinity to human insulin, activating intracellular signalling that increases glucose uptake in muscle and adipose tissue, suppresses hepatic glucose production an…
Indications compared
Semaglutide: Semaglutide is approved in adults with type 2 diabetes, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control. Insulin Glargine: Insulin glargine is approved as basal insulin therapy in adults and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus when oral or non-insulin injectable therapy is insufficien…
Safety profile
Semaglutide: The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, usually mild to moderate and tending to attenuate over weeks. Insulin Glargine: Hypoglycaemia is the most important adverse effect of any insulin and can be severe in case of missed meals, prolonged exercise, alcohol intake or interaction with other glucose-lowering agents.
Frequently asked questions
Is Semaglutide better than Insulin Glargine? ▾
Semaglutide and Insulin Glargine are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Semaglutide and Insulin Glargine be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Semaglutide
Products with Insulin Glargine
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.